PRESS-RELEASE ·Filed Jul 21, 2026
Press release · FDA
Actionable Insight • Neutral
This is a routine operational update with no new data.
Final — all horizons settled through T+60d
RNTX ▼ -15.67% at T+60d
NEUTRAL call -15.67% · α vs SPY -19.64% · entry $0.8948 → $0.7546
T+1d
-6.12%
call -6.12% · α -6.01%
$0.8400
settled 3mo ago
T+5d
-12.65%
call -12.65% · α -11.42%
$0.7816
settled 3mo ago
T+20d
-13.94%
call -13.94% · α -16.50%
$0.7701
settled 2mo ago
T+60d
-15.67%
call -15.67% · α -19.64%
$0.7546
settled 13d ago
Price Chart
Loading chart...
Executive Summary
Rein Therapeutics announced that its Phase 2 RENEW trial for inhaled LTI-03 in IPF is now open in Germany, completing the planned five-country expansion. The company remains on track to report initial topline data in the second half of 2026.
Key Facts
- Phase 2 RENEW trial for inhaled LTI-03 in IPF now enrolling in Germany, completing all five planned countries (US, UK, Australia, Poland, Germany).
- Topline data expected in 2H 2026.
- Study targets ~120 patients; primary endpoint is change in forced vital capacity (FVC).
- LTI-03 has Orphan Drug Designation in the US; no financial data or guidance provided.
Financial Impact
No financial data disclosed; clinical-stage company with no revenue.
Risk Factors
- Phase 2 trial may fail to meet endpoints, leading to significant downside.
- Enrollment delays or data readout postponement could disappoint.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330367 |
11 reports for RNTX
100% Hit rate @ T+60 Went positive at some point 4 of 4 best @ T+60▲ +25.69%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.7042 (−20.80%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.7042 (−12.63%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.7042 (−21.30%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.7042 (−25.77%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.7042 (+30.96%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.7042 (+30.96%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.7042 (+31.63%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 28, 2026 26w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.7042 (−52.74%) |
Showing 10 of 11
US Market Status
Market Closed — Opens Wed (15h 36m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers